Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.47 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | UBE2N | P61088 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL442392 | 0.87 | HTR6 (0.50) | ALDH1A1NOD1CXCL8HTTL3MBTL1 | |
| SCHEMBL10768316 | 0.84 | CXCL8 (0.50) | ALDH1A1SMN1; SMN2NOD1CXCL8HTT | |
| SCHEMBL28971544 | 0.80 | LMNA (0.46) | GAAALDH3A1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL28273198 | 0.72 | GAA (0.49) | GAAALDH3A1ALDH1A1SMN1; SMN2NOD1 | |
| SCHEMBL3624022 | 0.72 | CA1 (0.42) | HTTL3MBTL1POLBCA1CA2 | |
| SCHEMBL29414854 | 0.71 | HTR6 (0.75) | ALDH3A1ALDH1A1NOD1HTTL3MBTL1 | |
| SCHEMBL1673252 | 0.71 | HTR6 (0.75) | ALDH3A1ALDH1A1NOD1HTTL3MBTL1 | |
| SCHEMBL28414053 | 0.71 | NOD1 (0.61) | GAAALDH3A1ALDH1A1SMN1; SMN2NOD1 | |
| SCHEMBL1203289 | 0.70 | HTR6 (0.73) | ALDH3A1ALDH1A1NOD1HTTL3MBTL1 | |
| SCHEMBL28775093 | 0.70 | PPARG (0.48) | ALDH1A1SMN1; SMN2HTTHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399431-B1 | NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2009-02-18 | — | — | EP | claimed |
| US-7279472-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-10-09 | — | — | US | claimed |
| US-6982263-B2 | Nitriles useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-01-03 | — | — | US | claimed |
| US-20050032792-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | claimed |
| US-20050032772-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | claimed |
| US-6756372-B2 | FOR THERAPY OF AUTOIMMUNE DISEASES, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, OSTEOPOROSIS, RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, CROHN'S DISEASE, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, GUILLAIN-BARRE SYNDROME, PSORIASIS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | claimed |
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | claimed |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | claimed |
| EP-1218372-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2003-07-02 | — | — | EP | claimed |
| US-20030119827-A1 | Novel nitriles useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | claimed |
| US-6420364-B1 | TREATING AUTOIMMUNE DISEASES,ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, OSTEOPOROSIS, | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | claimed |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | EMMANUEL MICHEL JOSE (US) | 2002-05-16 | — | — | US | claimed |
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1399431-B1 | NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| US-6525052-B2 | Treating autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, and asthma | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| US-20020137932-A1 | Novel compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| US-6420364-B1 | TREATING AUTOIMMUNE DISEASES,ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, OSTEOPOROSIS, | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | EMMANUEL MICHEL JOSE (US) | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032772-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | GAA 172/4885ALDH3A1 1719/4885ALDH1A1 2061/4885 |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | GAA 176/4885ALDH3A1 1663/4885ALDH1A1 1811/4885 |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | GAA 2608/4885ALDH3A1 1543/4885ALDH1A1 584/4885 |
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | GAA 176/4885ALDH3A1 1663/4885ALDH1A1 1811/4885 |
| US-20030119827-A1 | Novel nitriles useful as reversible inhibitors of cysteine proteases | NOS1, CTSK, CTSS | GAA 1916/4885ALDH3A1 3441/4885ALDH1A1 3665/4885 |
| US-20050032792-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | GAA 167/4885ALDH3A1 1749/4885ALDH1A1 1878/4885 |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | GAA 176/4885ALDH3A1 1663/4885ALDH1A1 1811/4885 |
| US-20020137932-A1 | Novel compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | GAA 361/4885ALDH3A1 3359/4885ALDH1A1 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.